Eli Lilly has committed to setting a new standard for on-screen representation of common chronic diseases, and it walked the walk with its recent sponsorship of a segment on “Project Runway.” In the ...

We may receive a commission on purchases made from links. Beats recently launched the Powerbeats Fit earbuds – the latest addition to the Powerbeats lineup. With that, the company now offers two ...

The social media star and advocate — who shares her experience with arteriovenous malformation (AVM) — hit the catwalk in a stunning tulle gown Starr Bowenbank is the Style Editor at PEOPLE. She ...

Apple's Beats brand has a new set of fitness-focused earbuds available, the Powerbeats Fit. We picked up a set of the Powerbeats Fit to see how they compare to the prior-generation Beats Fit Pro and ...

UnitedHealth's Optum Rx makes money on the "spread" — the difference between the list price and the net price after rebates. But what happens if TrumpRx and MFN pricing collapse that spread? Fewer ...

After teasing a rebranded Powerbeats Fit that appeared to be an updated version of its Beats Fit Pro earbuds last month, Apple's Beats brand is officially announcing the new Powerbeats Fit today.

Four years after Beats Fit Pro launched, Beats is now unveiling a rebrand for its popular earbuds in the form of the Powerbeats Fit. More than simply combining the Fit Pro earbuds with the Powerbeats ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...

Of the title character in “Lost Evangeline,” it is said she “lived a great life of the imagination.” You could say the same about Evangeline’s creator, Kate DiCamillo. The beloved, Minneapolis-based ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose. Lilly closed the trial on ...

Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a single patient, citing “strategic business reasons.” The study was designed to test bimagrumab, an asset Lilly acquired in ...

Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain ...